These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2357123)

  • 61. Clinical administration of epoetin alfa recombinant.
    Taylor BA; Weinstein SM
    J Intraven Nurs; 1992; 15(2):78-82. PubMed ID: 1564606
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nephrology nursing care plan and patient education plan for the patient receiving Epogen.
    Prowant BF; Gallagher NM; Binkley LS; Latham D; Nichols E
    ANNA J; 1991 Apr; 18(2):188-93. PubMed ID: 2025050
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cognitive function in dialysis patients. Case study of the anemic patient.
    Martin-Lester M
    ANNA J; 1997 Jun; 24(3):359-65; quiz 366. PubMed ID: 9238909
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Review of patients' responses to epoetin alfa therapy.
    Krantz SB
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Categorizing the response to Epoetin alfa therapy. Case study of the anemic patient.
    Watson C
    ANNA J; 1999 Dec; 26(6):629-32. PubMed ID: 10876477
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of EPOGEN for treatment of anemia associated with chronic renal failure.
    Erlich L
    Crit Care Nurs Clin North Am; 1990 Mar; 2(1):101-13. PubMed ID: 2357306
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Managing anemia using laboratory trend analysis. Case study of the anemic patient.
    Aiello J
    ANNA J; 1999 Aug; 26(4):430-3. PubMed ID: 10838975
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Jones M; Ibels L; Schenkel B; Zagari M
    Kidney Int; 2004 Mar; 65(3):757-67. PubMed ID: 14871396
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
    Bieber E
    J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Administration of Epoetin alfa. Case study of the anemic patient.
    Cutler M
    ANNA J; 1997 Aug; 24(4):459-65; quiz 466. PubMed ID: 9325701
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Case management of the anemic patient. Epoetin alfa: focus on dialysis efficiency.
    Latham D; Geisman J
    ANNA J; 1991 Dec; 18(6):588-9. PubMed ID: 1750793
    [TBL] [Abstract][Full Text] [Related]  

  • 77. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
    Larson K
    Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Health care outcomes case study: anemia in end-stage renal disease.
    Turco TF
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S19-23. PubMed ID: 8846242
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Case study of the anemic patient: epoetin alfa--focus on sexual function.
    Zarifian A
    ANNA J; 1994 Oct; 21(6):368-71. PubMed ID: 7993143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.